Vanda Pharmaceuticals Inc.
VNDADrugs in Pipeline
21
Phase 3 Programs
13
Upcoming Catalysts
5
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
7 upcoming, 0 past
VNDA Earnings Report
EPS Est: $-0.50 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
6 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How VNDA's past catalysts played out
Ponesimod
Moderate-to-severe Chronic Plaque Psoriasis
iloperidone
Schizophrenia
Open Label Tradipitant
Idiopathic Gastroparesis
Tradipitant
Motion Sickness
Imsidolimab high dose
Generalized Pustular Psoriasis
VQW-765
Performance Anxiety
20 mg VEC-162
Insomnia
Tasimelteon Oral Suspension
Insomnia Disorder
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension
Autism Spectrum Disorder
Ziprasidone
Schizophrenia
VEC-162 20 mg
Primary Insomnia
Tasimelteon
Sleep Wake Disorders
Milsaperidone
Major Depressive Disorder (MDD)
VSJ-110
Dry Eye
Imsidolimab
Acne Vulgaris
Trichostatin A
Onychomycosis of Toenail
VSF-173
Excessive Somnolence
VLY-686 (Tradipitant)
Gastroparesis
VCA-894A
Charcot Marie Tooth Disease (CMT)
VLY-686
Treatment-resistant Pruritus Associated With Atopic Dermatitis
VEC-162
Circadian Rhythm Sleep Disorders
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ponesimod | Phase 3 | Moderate-to-severe Chronic Plaque Psoriasis | - | - |
iloperidone | Phase 3 | Schizophrenia | - | - |
Open Label Tradipitant | Phase 3 | Idiopathic Gastroparesis | - | - |
Tradipitant | Phase 3 | Motion Sickness | - | - |
Imsidolimab high dose | Phase 3 | Generalized Pustular Psoriasis | - | - |
VQW-765 | Phase 3 | Performance Anxiety | - | - |
20 mg VEC-162 | Phase 3 | Insomnia | - | - |
Tasimelteon Oral Suspension | Phase 3 | Insomnia Disorder | - | - |
Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Phase 3 | Autism Spectrum Disorder | - | - |
Ziprasidone | Phase 3 | Schizophrenia | - | - |
VEC-162 20 mg | Phase 3 | Primary Insomnia | - | - |
Tasimelteon | Phase 3 | Sleep Wake Disorders | - | - |
Milsaperidone | Phase 3 | Major Depressive Disorder (MDD) | - | - |
VSJ-110 | Phase 2 | Dry Eye | - | - |
Imsidolimab | Phase 2 | Acne Vulgaris | - | - |
Trichostatin A | Phase 2 | Onychomycosis of Toenail | - | - |
VSF-173 | Phase 2 | Excessive Somnolence | - | - |
VLY-686 (Tradipitant) | Phase 2 | Gastroparesis | - | - |
VCA-894A | Phase 2 | Charcot Marie Tooth Disease (CMT) | - | - |
VLY-686 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis | - | - |
VEC-162 | Phase 2 | Circadian Rhythm Sleep Disorders | - | - |
Generalized Pustular Psoriasis
1 drug in this indication
prevention of vomiting induced by motion
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Vanda Pharmaceuticals Inc.'s drug pipeline?→
CatalystAlert tracks 21 drug candidates in Vanda Pharmaceuticals Inc.'s (VNDA) pipeline across Phase 3, Phase 2. Its lead program is Ponesimod (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vanda Pharmaceuticals Inc.'s next FDA catalyst?→
Vanda Pharmaceuticals Inc.'s (VNDA) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VNDA biotech catalysts?→
Add VNDA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vanda Pharmaceuticals Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.